Genentech’s Actemra first biologic therapy FDA approved for slowing pulmonary functions decline
– Systemic sclerosis (SSc) is a rare disease that impacts up to 75,000 people in the United States –
– Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung func…